Explore. Learn. Join the conversation.

Working Group on New TB Drugs

Stop TB Partnership

TB Edition of The Lancet Infectious Diseases

Click to access links and audio from Lancet ID TB Edition

To commemorate World TB Day 2013, The Lancet Infectious Diseases publishes a Series of papers on tuberculosis, a disease that has long plagued human beings and was declared a global emergency in 1993 by WHO.

Launch of the Good Participatory Practice Guidelines for TB Drug Trials

cptr gpp tb

The Stakeholder and Community Engagement Workgroup of the Critical Path to TB Drug Regimens initiative launches guidelines that will facilitate the involvement of communities and participants in the conduct of TB drug trials.

21 Mar 2012
by Working Group

Posted in Announcements, Events, TB Drug Development, TB News

World TB Day Coverage: New Combo TB Drug Trial Announced

img_0842

During the “Cure All: A briefing on the status of the most promising new TB drugs research” sponsored by the Critical Path to New TB Drug Regimens (CPTR) on Monday, March 19, Dr. Mel Spigelman, CEO & President, of TB Alliance announced the launch of the NC002 trial, a combination drug trial that establishes a new pathway to TB and multi-drug resistant TB treatment. The meeting also involved high-level officials from U.S. agencies that support TB research including Anthony Fauci (Director, NIAID/NIH), Janet Woodcock (Director, CDER/FDA), and Robert Clay (Deputy Assistant Administrator, Global Health Bureau/USAID).

27 Jan 2012
by Working Group

Posted in Announcements, Events, TB Drug Development, TB News

Summary Available! TB Clinical Trials Consultants Meeting

Businesswoman Talking During Meeting

On November 17 and 18, a TB Clinical Trials Consultants Meeting was held at St. George’s, University of London. The meeting was organized by CDC, CPTR, INTERTB, NIH, and TB Alliance. The meeting was convened to catalog expert opinion on the conduct of Phase 2 and Phase 3 clinical trials in tuberculosis.

10 Nov 2010
by Working Group

Posted in TB News, Video

First Novel Regimen Clinical Trial Featured on South African TB

The clinical trial of the first novel regimen was featured today on SABC TV in South Africa. This is the first clinical trial to test multiple new TB drugs in combination; the trial is known as New Combination 1 (NC001). The experimental regimen undergoing testing in this trial consists of experimental TB drugs PA-824, Moxifloxacin, and Pyrazinamide, an antibiotic commonly administered as part of current TB treatment.

8 Nov 2010
by TB Alliance

Posted in Front Lines of TB R&D, TB News, TB Treatment, Video

TB Alliance Launches First Clinical Trial of a Novel TB Drug Regimen

Today, the TB Alliance announced the first clinical trial to test multiple new TB drugs in combination; the trial is known as New Combination 1 (NC001).The experimental regimen undergoing testing in this trial consists of experimental TB drugs PA-824, Moxifloxacin, and Pyrazinamide, an antibiotic commonly administered as part of current TB treatment. This regimen has shown potential to harmonize treatment for TB drug-sensitive tuberculosis (DS-TB) and multidrug-resistant tuberculosis (MDR-TB) under a single three-drug regimen.

11 Aug 2010
by Working Group

Posted in Front Lines of TB R&D

This week in TB R&D – 10 August 2010

This week we reposted an article from DailyFinance.com regarding a new antibactierial compound from GlaxoSmithKline (GSK). GSK has recently published a Nature paper describing the 2.1 angstom crystal structure of Staphylococcus aureus DNA gyrase (a Type IIA topoisomerase) and DNA in complex with their new broad-spectrum antibacterial compound (GSK299423).

25 Mar 2010
by Khisi Mdluli

Posted in Front Lines of TB R&D

Impact of the CPTR Initiative

After a decades-long drought, new pharmaceutical discoveries and repurposing of existing antimicrobials have produced about 10 drugs from 7 different classes which are now in various stages of clinical development for TB.

18 Mar 2010
by Working Group

Posted in Front Lines of TB R&D, TB News

Launch of the Critical Path to TB Drug Regimens

Today marks the launch of an exciting new initiative in TB R&D. The US Food and Drug Administration (FDA) has supported the Critical Path to TB Drug Regimens (CPTR). The CPTR comprises a broad collaborative network of partners including pharmaceutical companies, government, academia, and advocates, and NGOs with the focus to accelerate the development of new, safe, and highly effective shorter length TB treatment regimens.